克拉霉素转换治疗呼吸道肺炎支原体感染的临床观察  

The clinical observation about Clarithromycin conversion treatment of respiratory tract mycoplasma pneumoniae infection

作　　者：李师燕[1] 

机构地区：[1]广东省东莞市虎门医院,广东东莞523900

出　　处：《中国医药导报》2009年第18期72-73,共2页China Medical Herald

摘　　要：目的:观察克拉霉素转换治疗呼吸道肺炎支原体感染的临床疗效。方法:选取我院门诊、住院患儿中诊断呼吸道肺炎支原体感染者80例为研究对象,随机分为治疗组40例和对照组40例,两组开始均用头孢呋辛钠配合阿奇霉素3～5d静脉输液,然后治疗组转为克拉霉素口服治疗,对照组转为阿奇霉素口服治疗。结果:克拉霉素转换治疗组和阿奇霉素序贯治疗组疗效一致,但序贯治疗组阿奇霉素胃肠反应大,副作用多,易形成耐药性,患儿及家属难以接受。结论:克拉霉素转换治疗应作为目前治疗呼吸道肺炎支原体感染的有效方法,值得推广。Objective： To observe the clinical efficacy of Clarithromycin conversion treatment of respiratory tract mycoplas- ma pneumoniae infection. Methods： We selected our hospital out-patient and hospitalization in children with respiratory tract mycoplasma pneumoniae infection in diagnosis,and randomly divided into treatment group and control group,both groups started with Azithromycin Cefuroxime intravenous infusion 3-5 days,and then the treatment group to Clarithromycin oral treatment,the control group to oral treatment with Azithromycin. Results： The efficacy of the two groups was agreed, however, the control group Azithromycin major gastrointestinal reactions, more side effects,easy to form resistance,patients and their families could not accept. Conclusion： Clarithromycin conversion therapy should be used as the current treatment of respiratory tract mycoplasma pneumoniae infection in an effective way,it is worth promoting.

关 键 词：克拉霉素 阿奇霉素 转换治疗 肺炎支原体 呼吸道感染 

分 类 号：R518.9[医药卫生—内科学]